BMS-378806

BMS-378806 (also known as BMS-806) is a small molecule HIV-1 attachment inhibitor originally developed by Bristol Myers Squibb. It functions by selectively binding to the HIV-1 envelope glycoprotein gp120, which prevents the viral protein from interacting with the host cell's CD4 receptor. This action blocks the initial step of viral entry into T-cells. BMS-378806 demonstrates potent antiviral activity against a broad range of HIV-1 subtypes, including R5, X4, and dual-tropic strains, while remaining inactive against HIV-2 and SIV. Although it was initially investigated as an oral therapy for HIV-1 infection, its clinical development was ultimately discontinued.

Other names

4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine